Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
Nelson CH, Etchevers K, Yi S, Breckenridge D, Hepner M, Patel U, Ling J, Mathias A. Nelson CH, et al. Among authors: mathias a. Clin Pharmacokinet. 2020 Sep;59(9):1109-1117. doi: 10.1007/s40262-020-00878-y. Clin Pharmacokinet. 2020. PMID: 32333325 Clinical Trial.
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A. Mogalian E, et al. Among authors: mathias a. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02084-16. doi: 10.1128/AAC.02084-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28193657 Free PMC article. Clinical Trial.
Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection.
German P, Xin Y, Chien JW, Weng W, Mackman R, Lewis SA, Meng A, Ling J, Mathias A. German P, et al. Among authors: mathias a. J Clin Pharmacol. 2018 Aug;58(8):1025-1034. doi: 10.1002/jcph.1112. Epub 2018 Apr 17. J Clin Pharmacol. 2018. PMID: 29663420
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Reyes M, Lutz JD, Lau AH, Gaggar A, Grant EP, Joshi A, Mackman RL, Ling J, Tan SK, Ayithan N, Daffis S, Woo J, Wu P, Lam T, Fletcher SP, Kottilil S, Poonia B, Gane EJ, Mathias A, German P. Reyes M, et al. Among authors: mathias a. Antivir Ther. 2020;25(3):171-180. doi: 10.3851/IMP3363. Antivir Ther. 2020. PMID: 32667286 Clinical Trial.
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A, Anderson K, Nelson C, Ni L, Chuang SM, Bellanti F, Chang P, Comisar C, Kearney BP, Bartok B, Mathias A. Meng A, et al. Among authors: mathias a. Br J Clin Pharmacol. 2022 Jul;88(7):3211-3221. doi: 10.1111/bcp.15239. Epub 2022 Feb 14. Br J Clin Pharmacol. 2022. PMID: 35072287 Free PMC article. Clinical Trial.
300 results